Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 3, 2024. 

NeurologyLive® Friday 5 — May 3, 2024

Videos

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

Recent preclinical findings revealed SBT-589's potential to treat cardiomyopathy in Friedreich ataxia by targeting mitochondrial dysfunction.

Stealth BioTherapeutics’ SBT-589 Shows Cardioprotective Effects in Preclinical Models of Friedreich Ataxia 

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

Using a Blood Collection Device to Advance Genetic Research in Parkinson Disease: James Beck, PhD & Ben Casavant, PhD

, has been with the team since October 2019. Follow him on Twitter 

Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic 

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.

NeurologyLive and CMSC Announce the 3rd Annual Giants of MS Class of Inductees

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

1rem

An expert neurologist discusses the use of targeted therapies to personalize treatment for patients with generalized myasthenia gravis (gMG) and reviews the impact on quality of life, the challenges of managing the disease, as well as new and emerging therapies.

Personalizing Myasthenia Gravis Treatment with Targeted Therapies

A physician expert discusses the socioeconomic burden of gMG on both the patient and the caregiver.

Impact of Generalized Myasthenia Gravis (gMG) on Quality of Life

An expert comments on the impact of factors such as disease course, antibody status, and patient adherence on the management of gMG.

Considerations for Approaching the Management of gMG

An expert reviews targeted therapies in generalized myasthenia gravis, highlighting complement and neonatal Fc receptors.

Therapeutic Strategies in gMG

An expert neurologist comments on the need for generalized myasthenia gravis treatment to be tailored to the patient to alleviate symptoms without significant adverse effects.

Personalizing gMG Treatment

James F. Howard Jr, MD, discusses both intravenous and subcutaneous efgartigimod for the treatment of gMG.

Subcutaneous Efgartigimod for Treatment of gMG

An expert neurologist reviews efficacy and safety data of rozanolixizumab, an FcRn-targeting agent approved for treatment of gMG, as well as how it differs from efgartigimod.

Other FcRn Targeting Agents gMG

James F. Howard Jr, MD, shares thoughts on the future of the treatment of gMG, highlighting the renewed interest in the disease landscape.

Future of gMG Treatment